$MANE News

Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics (MANE) Positioned to Disrupt Hair Loss Market

Veradermics (MANE) Price Target Increased by 23.12% to 166.77

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss - Slideshow

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics: VDPHL01 Looks Promising Enough On Paper

Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss

Citigroup Maintains Buy on Veradermics, Raises Price Target to $160

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Needham Maintains Buy on Veradermics, Raises Price Target to $164

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027

B. Riley Securities Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $170

Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Jefferies Maintains Buy on Veradermics, Raises Price Target to $182

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?